Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Solid Biosciences (Nasdaq: SLDB) announced that President and CEO Bo Cumbo will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced that President and CEO Bo Cumbo will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available on the company's Investors Events page, and a replay will be archived for 30 days.
This presentation provides investors and analysts access to management commentary and updates via webcast.
Details
News Market Reaction – SLDB
On Jan 6, the day this news came out, SLDB closed 3.00% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference date
- January 13, 2026
- Scheduled J.P. Morgan Healthcare Conference presentation date
- Presentation time PT
- 5:15 p.m. PT
- Scheduled start time of conference presentation
- Presentation time ET
- 8:15 p.m. ET
- Eastern Time equivalent for presentation
- Replay duration
- 30 days
- Webcast replay availability on company website
Historical Context
-
Duchenne muscular dystrophy added to the U.S. newborn screening panel.
-
Presentations on AAV-SLB101 and cardiac gene therapy pipeline at CVCT Forum.
-
RSU inducement awards to new hires under the 2024 Inducement Plan.
-
FDA Rare Pediatric Disease designation for SGT-212 gene therapy in FA.
-
Non-exclusive license of AAV-SLB101 to Andelyn Biosciences for client use.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.